Update on role of chemotherapy in head and neck squamous cell cancer

Indian Journal of Surgical Oncology

Volumn 1, Issue 2, 2010, Pages 85-95

  Marur, S ^a   Forastiere, A A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

cetuximab; chemoradiation; chemotherapy; Head and neck cancer; induction chemotherapy; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; LAPATINIB; MATUZUMAB; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNINDEXED DRUG;

AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HAZARD RATIO; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SURGERY; HUMAN; LARYNGECTOMY; LARYNX CANCER; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; ORGAN PRESERVATION; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TONGUE CANCER; TONSIL CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84861113464     PISSN: 09757651     EISSN: 09766952     Source Type: Journal    
DOI: 10.1007/s13193-010-0021-y     Document Type: Review

References (79)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.
2. Jemal A, Siegal R, Ward E, Murray T, Zu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
3. Wittes R, Heller K, Randolp V, Howard J, Vallejo A, Farr H, et al. cis-Dichlorodiammineplatinum (11)-based chemotherapy as initial treatment in advanced head and neck cancer. Cancer Treat Rep. 1979; 63: 1533-1538.
4. Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am. 1991; 5: 667-668.
5. Rosenthal DI, Pistenmaa DA, Glatstein E. A review of neoadjuvant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner. Int J Radiat Oncol Biol Phys. 1994; 28: 315-320.
6. Vokes E, Haraf D, Weichselbaum R, Brachman D. Induction chemotherapy: promises and limitations. In Head and neck cancer (eds) Johnson JT, Didolkar MS), Amsterdam/London, Excerpta Medica; 1993; pp. 321-326.
7. Beitler JJ, Cooper JS. Seduction by induction? J Clin Oncol. 2009; 27: 9-10.
8. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991; 324: 1685-1690.
9. Lefebvre JL, Chevalier D, Luboinski B, Traissac L, Andry G, De Raucourt D, et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. J Clin Oncol. 2004; 22: 5531.
10. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-2098.
11. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Silieni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994; 86: 265-272.
12. Zorat PL, Pacagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717.
13. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer. 2000; 83: 1594-1598.
14. Vermoken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Eng J Med. 2007; 357: 1695-1704.
15. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Eng J Med. 2007; 357: 1705-1715.
16. Pointreau, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009; 101: 498-506.
17. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709-720.
18. Anaya-Saavedra G, Ramirez-Amador V, Irigoyen-Camacho ME, Garcia-Cuellar CM, Guido-Jimenez M, Mendez-Martinez R, et al. High association of human papillomavirus infection with oral cancer: a case-control study. Arch Med Res. 2008; 39: 189-197.
19. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'souza G, Gravitt PE, et al. Squamous Cell Head and Neck Cancer and the Human Papillomavirus: Summary of a State of the Science Meeting, 9-10 November 2008, Washington, D. C. Head Neck, Publication pending.
20. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive quamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001; 92: 805-813.
21. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261-269.
22. Kies MS, Garden AS, Holsinger C, Papadimitrakopoulou V, El-Naggar AK, Gillaspy K, et al. Induction chemotherapy (CT) with weekly pa clitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). J Clin Oncol. 2006; 24: 5520.
23. Wanebo HJ, Ghebremichael M, Burtness B, Spencer S, Ridge J, Forastiere A, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol. 2007; 25: 6015.
24. Argiris E, Gibson MK, Heron DE, Smith RP, Ferris RL, Lai SY, et al. Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). J Clin Oncol 2008; 26: 6002.
25. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002; 20: 1845-1852.
26. Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 2004; 22: 3053-3060.
27. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000; 18: 1458-1464.
28. Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004; 22: 4665-4673.
29. Adelstein D J, Li Y, Adams GL, Wagner Jr H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.
30. Forastiere AA, Maor M, Weber RS, Pajak T, Glisson B, Trotti A, et al. Long-term results of intergroup RTOG 91-11: A phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy. J Clin Oncol. 2006; 24: 5517.
31. Bonner JA, Harrari PM, Giralt J, Azarnia N, Shin DM, Cohn RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med. 2006; 354: 567-578.
32. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 1798-1804.
33. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy. Bull Cancer. 2000; 87: 48-53.
34. Starr S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-andneck cancer. Int J Radiat Oncol Biol Phys. 2001; 50: 1161-1171.
35. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004; 22: 69-76.
36. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L., Sahmoud, T. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996; 88: 890-899.
37. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317.
38. Huncharek M, Kupelnick, B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1, 528 patients from six randomized trials. Am J Clin Oncol 2002; 25: 219-223.
39. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006; 64: 47-56.
40. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952.
41. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
42. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Campbell BH, Saxman SB, et al. Long-term survival results of a phase III intergroup trial (RTOG 95-01) of surgery followed by radiotherapy vs. radiochemotherapy for resectable high risk squamous cell carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys 2006; 66: S14-S15.
43. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27: 843-850.
44. Pignon JP, Bourhis C, Domenge C, Designe L, on behalf of the MACHNC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000; 355: 949-955.
45. Pignon JP, le Maitre A, Maillard E, Bourhis J on behalf of the MACHNC Collaborative Group. Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 radomised trials and 17, 346 patients. Radiotherapy and Oncology 2009; 92: 4-14.
46. Licitra, L, Locati, LD, Bossi, P. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: New options. Ann Oncol. 2008; 19Suppl 7: vii200-vii203.
47. Al-Sarraf M, Metch B, Kish J, Ensley J, Rinehart JJ, Schuller DE, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987; 71: 723-726.
48. Hong WK, Schaefer S, Issell B, Cummings C, Luedke D, Bromer R, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983; 52: 206-210.
49. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992; 10: 257-263.
50. Guardiola E, Peyrade, F, Chaigneau, L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004; 40: 2071-2076.
51. Zenda S, Onozawa Y, Boku N, Ebihara M, Onitsuka T. Single-agent docetaxel in patients with platinumrefractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol 2007; 37: 477-481.
52. Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial (PA390). Cancer. 1998; 82: 2270-2274.
53. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994; 5: 543-547.
54. Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother. 2005; 6: 85-92.
55. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001; 85: 649-655.
56. Le Tourneau C, Chen EX. Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am. 2008; 22: 1209-1220.
57. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 1987; 21: 1980-1987.
58. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004; 22: 77-85.
59. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamouscell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10: 1245-1251.
60. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992; 10: 257-263.
61. Gibson MK, Li Y, Murphy B, Hussain MHA, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 3562-3567.
62. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002; 20: 1593-1599.
63. Fountzilas G, Stathopoulos G, Nicolaides C, Kalogera-Fountzila A, Kalofonos H, Nikolaou A, et al. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 1999; 10: 475-478.
64. Labourey JL, Cupissol D, Calais G, Tourani JM, Kohser F, Borel C, et al. Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol. 2007; 30: 278-282.
65. Hitt R, Castellano D, Hidalgo M, Garcia-Carbonero R, Pena M, Brandariz A, et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol. 1998; 9: 1347-1349.
66. Genet D, Cupissol D, Calais G, Bontemps P, Bourgeois H, Dutin JP, et al. Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: A phase II multicenter study. Am J Clin Oncol. 2004; 27: 472-476.
67. Bentzen JD, Hansen HS. Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head Neck. 2007; 29: 47-51.
68. Hitt R, Jimeno A, Rodriguez-Pinilla M, Rodriguez-Peralto JL, Millan JM, Lopez-Martin A, et al. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer. 2004; 91: 2005-2011.
69. Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, et al. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer. 2006; 107: 319-327.
70. Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res. 2006; 26: 585-590.
71. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998; 16: 1325-1330.
72. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994; 5: 521-526.
73. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25: 2171-2177.
74. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 5578-5587.
75. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinumrefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23: 5568-5577.
76. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 2005; 23: 8646-8654.
77. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and cetuximab in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695-1704.
78. Cohen EE, Karrison TG, Wong SJ, Skoog-Sluman LJ, Kosloff MF, Dancey J, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). Lancet Oncol. 2009; 10: 247-257.
79. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Mauer AM, Dekker A, et al. A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). Proc Am Soc Clin Oncol. 2006; 24: 5530.